Comparing Avalon GloboCare (NASDAQ:ALBT) & Innate Pharma (NASDAQ:IPHA)

Innate Pharma (NASDAQ:IPHA) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.

Risk and Volatility

Innate Pharma has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.

Profitability

This table compares Innate Pharma and Avalon GloboCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Avalon GloboCare	-1,125.59%	N/A	-73.69%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Innate Pharma and Avalon GloboCare, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0	0	1	1	3.50
Avalon GloboCare	0	0	0	0	0.00

Innate Pharma currently has a consensus target price of $11.50, indicating a potential upside of 715.60%. Given Innate Pharma’s stronger consensus rating and higher probable upside, research analysts plainly believe Innate Pharma is more favorable than Avalon GloboCare.

Earnings and Valuation

This table compares Innate Pharma and Avalon GloboCare”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$66.71 million	1.71	-$8.19 million	N/A	N/A
Avalon GloboCare	$1.26 million	2.34	-$16.71 million	($19.96)	-0.14

Innate Pharma has higher revenue and earnings than Avalon GloboCare.

Institutional and Insider Ownership

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 37.3% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Innate Pharma beats Avalon GloboCare on 9 of the 12 factors compared between the two stocks.

About Innate Pharma

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.